Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 399.46 Million CNY | -9.81% |
| 2022 | 442.92 Million CNY | 21.96% |
| 2021 | 363.17 Million CNY | 61.26% |
| 2020 | 225.21 Million CNY | -14.76% |
| 2019 | 264.19 Million CNY | 41.08% |
| 2018 | 187.26 Million CNY | -25.23% |
| 2017 | 250.46 Million CNY | -25.03% |
| 2016 | 334.07 Million CNY | -30.58% |
| 2015 | 481.24 Million CNY | 16.92% |
| 2014 | 411.61 Million CNY | 16.44% |
| 2013 | 353.5 Million CNY | 0.32% |
| 2012 | 352.38 Million CNY | 28.12% |
| 2011 | 275.04 Million CNY | -48.09% |
| 2010 | 529.83 Million CNY | 70.87% |
| 2009 | 310.07 Million CNY | 35.84% |
| 2008 | 228.26 Million CNY | 1.75% |
| 2007 | 224.33 Million CNY | 44.99% |
| 2006 | 154.73 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 367.56 Million CNY | 136.17% |
| 2024 Q1 | -1.01 Billion CNY | -354.39% |
| 2023 Q2 | 393.54 Million CNY | 0.0% |
| 2023 Q4 | 399.46 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2023 FY | 399.46 Million CNY | -9.81% |
| 2023 Q1 | - CNY | -100.0% |
| 2022 Q2 | 369.92 Million CNY | 0.0% |
| 2022 Q4 | 442.92 Million CNY | 0.0% |
| 2022 FY | 442.92 Million CNY | 21.96% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2021 Q2 | 340.74 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 FY | 363.17 Million CNY | 61.26% |
| 2021 Q4 | 363.17 Million CNY | 0.0% |
| 2020 Q2 | 208.51 Million CNY | 0.0% |
| 2020 FY | 225.21 Million CNY | -14.76% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q4 | 225.21 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q2 | 216.37 Million CNY | 0.0% |
| 2019 Q4 | 264.19 Million CNY | 0.0% |
| 2019 FY | 264.19 Million CNY | 41.08% |
| 2018 Q2 | 239.1 Million CNY | 0.0% |
| 2018 FY | 187.26 Million CNY | -25.23% |
| 2018 Q4 | 187.26 Million CNY | 0.0% |
| 2018 Q1 | - CNY | -100.0% |
| 2017 Q2 | 329.12 Million CNY | 0.0% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 FY | 250.46 Million CNY | -25.03% |
| 2017 Q4 | 250.46 Million CNY | 0.0% |
| 2016 Q4 | 334.07 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 334.07 Million CNY | -30.58% |
| 2016 Q2 | 338.76 Million CNY | 0.0% |
| 2015 Q2 | 424.43 Million CNY | 0.0% |
| 2015 Q4 | 481.24 Million CNY | 0.0% |
| 2015 Q1 | - CNY | -100.0% |
| 2015 FY | 481.24 Million CNY | 16.92% |
| 2014 FY | 411.61 Million CNY | 16.44% |
| 2014 Q2 | 379.03 Million CNY | 0.0% |
| 2014 Q4 | 411.61 Million CNY | 0.0% |
| 2014 Q1 | - CNY | -100.0% |
| 2013 Q2 | 351.84 Million CNY | 0.0% |
| 2013 FY | 353.5 Million CNY | 0.32% |
| 2013 Q4 | 353.5 Million CNY | 0.0% |
| 2013 Q1 | - CNY | -100.0% |
| 2012 FY | 352.38 Million CNY | 28.12% |
| 2012 Q4 | 352.38 Million CNY | 0.0% |
| 2012 Q2 | 345.23 Million CNY | 0.0% |
| 2011 Q2 | 459.7 Million CNY | 0.0% |
| 2011 Q4 | 275.04 Million CNY | 0.0% |
| 2011 FY | 275.04 Million CNY | -48.09% |
| 2010 Q2 | 328.51 Million CNY | 0.0% |
| 2010 FY | 529.83 Million CNY | 70.87% |
| 2010 Q4 | 529.83 Million CNY | 0.0% |
| 2009 Q4 | 310.07 Million CNY | 0.0% |
| 2009 FY | 310.07 Million CNY | 35.84% |
| 2008 FY | 228.26 Million CNY | 1.75% |
| 2007 FY | 224.33 Million CNY | 44.99% |
| 2006 FY | 154.73 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -180.755% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 94.486% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -134.418% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | 43.71% |
| Qianhai Health Holdings Limited | 94 Million HKD | -324.948% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 57.05% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 55.801% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | 39.965% |
| PuraPharm Corporation Limited | 689.65 Million HKD | 42.077% |
| SSY Group Limited | 4.49 Billion HKD | 91.111% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -8.919% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 63.369% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.763% |